ERYTHROMYCIN
ERYTHROMYCIN is one of 8,063 medications in the MedPlain dataset. Key details — Brand name: ERYTHROMYCIN; Generic name: ERYTHROMYCIN; Drug class: Macrolide [EPC].
| Brand name | ERYTHROMYCIN |
|---|---|
| Generic name | ERYTHROMYCIN |
| Drug class | Macrolide [EPC] |
| Manufacturer | Golden State Medical Supply, Inc. |
| Used for | INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin delayed-release tablets and other antibacterial drugs, erythromycin delayed-release tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin delayed-release tablets are indicated in the treatment of infections caused by susce |
| Dosage | DOSAGE AND ADMINISTRATION In most patients, erythromycin delayed-release tablets, are well absorbed and may be dosed orally without regard to meals. However, optimal blood levels are obtained when erythromycin delayed-release tablets, 250 mg, erythromycin delayed-release tablets, 333 mg and erythromycin delayed-release tablets, 500 mg tablets are given in the fasting state (at least 1/2 hour and preferably 2 hours before meals). Adults The usual dose is 250 mg four times daily in equally spaced |
| Warnings | WARNINGS Hepatotoxicity There have been reports of hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or cholestatic hepatitis, with or without jaundice, occurring in patients receiving oral erythromycin products. QT Prolongation Erythromycin has been associated with prolongation of the QT interval and infrequent cases of arrhythmia. Cases of torsades de pointes have been spontaneously reported during postmarketing surveillance in patients receiving erythromycin. Fata |
| Active ingredient(s) | ERYTHROMYCIN |
| Route | ORAL |
| Official label | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0c0560be-fb11-509d-e063-6394a90ab6f7 |